Market Overview

Spruce Point: Dexcom Could Fall 45-60%

Share:
Spruce Point: Dexcom Could Fall 45-60%

DexCom, Inc. (NASDAQ: DXCM) shares are trading lower after a new report from Spruce Point Capital argued the stock could fall 45-60 percent.

The San Diego-based company manufacturers continuous glucose monitoring systems for diabetic patients.

Until now, the company’s G-Series model has been considered the gold standard, while its competitor Abbott Laboratories (NYSE: ABT) offered a cheaper, user-friendly alternative with the FreeStyle Libre, according to Spruce Point. 

Abbott is set to release the Libre 2 in the U.S. and Spruce Point said the launch will close most if not all technological gaps with Dexcom’s G-Series.

This move will put heavy pressure on Dexcom profits with little downside to Abbott's margin, the report said.

“The Street believes that the downmarket Libre is not a serious threat to Dexcom’s market, but the LIbre has taken [greater than 70 percent] incremental share of the U.S. Type 1 market and [greater than 95 percent] incremental share of the U.S. Type 2 market since first being released in the U.S." 

Dexcom has few avenues for near-term patient growth and will be effectively locked out of the Type 2 market until it releases a cheaper, downmarket CGM similar to the Libre, according to Spruce Point. 

“We see 45-60-percent near-term downside in DXCM shares after disappointing sales growth and a multiple re-rating, and even more potential future downside on long-term price pressure." 

DexCom shares were down 3.13 percent at $141.59 at the time of publication Thursday. 

Related Links:

The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings, IPOs

Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates

Photo courtesy of Dexcom. 

Latest Ratings for DXCM

DateFirmActionFromTo
Oct 2020Wells FargoDowngradesEqual-WeightUnderweight
Jul 2020Piper SandlerMaintainsOverweight
Jul 2020UBSMaintainsNeutral

View More Analyst Ratings for DXCM
View the Latest Analyst Ratings

 

Related Articles (DXCM + ABT)

View Comments and Join the Discussion!

Posted-In: G-SeriesAnalyst Color Short Sellers Short Ideas Health Care Analyst Ratings Trading Ideas General Best of Benzinga

Latest Ratings

StockFirmActionPT
CMGDeutsche BankMaintains1,235.0
GMBarclaysMaintains40.0
FBarclaysMaintains9.0
AAPLPiper SandlerMaintains135.0
ALGNPiper SandlerMaintains500.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com